{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T17:57:45Z","timestamp":1768499865613,"version":"3.49.0"},"posted":{"date-parts":[[2022,8,9]]},"group-title":"Immunology","reference-count":44,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>The global SARS-CoV-2 pandemic prompted rapid development of COVID-19 vaccines. Although several vaccines have received emergency approval through various public health agencies, the SARS-CoV-2 pandemic continues. Emergent variants of concern, waning immunity in the vaccinated, evidence that vaccines may not prevent transmission and inequity in vaccine distribution have driven continued development of vaccines against SARS-CoV-2 to address these public health needs. In this report, we evaluated a novel self-amplifying replicon RNA vaccine against SARS-CoV-2 in a pigtail macaque model of COVID-19 disease. We found that this vaccine elicited strong binding and neutralizing antibody responses. While binding antibody responses were sustained, neutralizing antibody waned to undetectable levels after six months but were rapidly recalled and conferred protection from disease when the animals were challenged 7 months after vaccination as evident by reduced viral replication and pathology in the lower respiratory tract, reduced viral shedding in the nasal cavity and lower concentrations of pro-inflammatory cytokines in the lung. Cumulatively, our data demonstrate in pigtail macaques that a self-amplifying replicon RNA vaccine can elicit durable and protective immunity to SARS-CoV-2 infection. Furthermore, these data provide evidence that this vaccine can provide durable protective efficacy and reduce viral shedding even after neutralizing antibody responses have waned to undetectable levels.<\/jats:p>","DOI":"10.1101\/2022.08.08.503239","type":"posted-content","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T18:55:11Z","timestamp":1660071311000},"source":"Crossref","is-referenced-by-count":2,"title":["A replicon RNA vaccine induces durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned"],"prefix":"10.64898","author":[{"given":"Megan A.","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Hawman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Meade-White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanna","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Randall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Archer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas B.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brieann","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Iwayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Wangari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn A.","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Lovaglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Saturday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul T.","family":"Edlefsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Khandhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah Heydenburg","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse H.","family":"Erasmus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2022081112050635000_2022.08.08.503239v1.1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","year":"2022","journal-title":"Science"},{"key":"2022081112050635000_2022.08.08.503239v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-020-03041-6"},{"key":"2022081112050635000_2022.08.08.503239v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.040"},{"key":"2022081112050635000_2022.08.08.503239v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2103916"},{"key":"2022081112050635000_2022.08.08.503239v1.5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"2022081112050635000_2022.08.08.503239v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2022081112050635000_2022.08.08.503239v1.7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cell.2021.12.002","article-title":"Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung","volume":"185","year":"2022","journal-title":"Cell"},{"key":"2022081112050635000_2022.08.08.503239v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S01406736(21)01642-1"},{"key":"2022081112050635000_2022.08.08.503239v1.9","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cmi.2021.06.036","article-title":"BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel","volume":"27","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2022081112050635000_2022.08.08.503239v1.10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(22)00090-3","article-title":"Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose","volume":"399","year":"2022","journal-title":"The Lancet"},{"key":"2022081112050635000_2022.08.08.503239v1.11","doi-asserted-by":"crossref","unstructured":"J. H. Erasmus et al., An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci Transl Med 12, (2020).","DOI":"10.1126\/scitranslmed.abc9396"},{"key":"2022081112050635000_2022.08.08.503239v1.12","unstructured":". (2022)."},{"key":"2022081112050635000_2022.08.08.503239v1.13","doi-asserted-by":"crossref","unstructured":"H. F. Tseng et al., Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med, (2022).","DOI":"10.1101\/2022.01.07.22268919"},{"key":"2022081112050635000_2022.08.08.503239v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.06.011"},{"key":"2022081112050635000_2022.08.08.503239v1.15","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"2022081112050635000_2022.08.08.503239v1.16","doi-asserted-by":"crossref","first-page":"681516","DOI":"10.3389\/fimmu.2021.681516","article-title":"Cytokine Signature Associated With Disease Severity in COVID-19","volume":"12","year":"2021","journal-title":"Front Immunol"},{"key":"2022081112050635000_2022.08.08.503239v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0779-1"},{"key":"2022081112050635000_2022.08.08.503239v1.18","doi-asserted-by":"crossref","unstructured":"Y. Wu et al., A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci Transl Med 13, (2021).","DOI":"10.1126\/scitranslmed.abg1143"},{"key":"2022081112050635000_2022.08.08.503239v1.19","doi-asserted-by":"crossref","unstructured":"D. W. Hawman et al., SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern. Elife 11, (2022).","DOI":"10.7554\/eLife.75537"},{"key":"2022081112050635000_2022.08.08.503239v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y"},{"key":"2022081112050635000_2022.08.08.503239v1.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26178-y"},{"key":"2022081112050635000_2022.08.08.503239v1.22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","year":"2020","journal-title":"Nature"},{"key":"2022081112050635000_2022.08.08.503239v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2607z"},{"key":"2022081112050635000_2022.08.08.503239v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.026"},{"key":"2022081112050635000_2022.08.08.503239v1.25","doi-asserted-by":"crossref","unstructured":"P. J. Klasse , D. F. Nixon , J. P. Moore , Immunogenicity of clinically relevant SARS-CoV- 2 vaccines in nonhuman primates and humans. Sci Adv 7, (2021).","DOI":"10.1126\/sciadv.abe8065"},{"key":"2022081112050635000_2022.08.08.503239v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21111-9"},{"key":"2022081112050635000_2022.08.08.503239v1.27","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd7728"},{"key":"2022081112050635000_2022.08.08.503239v1.28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/jiaa618","article-title":"Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection","volume":"223","year":"2021","journal-title":"J Infect Dis"},{"key":"2022081112050635000_2022.08.08.503239v1.29","doi-asserted-by":"crossref","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"373","year":"2021","journal-title":"Science"},{"key":"2022081112050635000_2022.08.08.503239v1.30","doi-asserted-by":"crossref","unstructured":"G. J. Rieke et al., Induction of NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 after natural infection is more potent than after vaccination. J Infect Dis, (2022).","DOI":"10.1093\/infdis\/jiac060"},{"key":"2022081112050635000_2022.08.08.503239v1.31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","year":"2021","journal-title":"Nature"},{"key":"2022081112050635000_2022.08.08.503239v1.32","doi-asserted-by":"crossref","first-page":"e1009509","DOI":"10.1371\/journal.ppat.1009509","article-title":"Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread","volume":"17","year":"2021","journal-title":"PLoS Pathog"},{"key":"2022081112050635000_2022.08.08.503239v1.33","doi-asserted-by":"crossref","unstructured":"A. Chandrashekar et al., Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell, (2022).","DOI":"10.1016\/j.cell.2022.03.024"},{"key":"2022081112050635000_2022.08.08.503239v1.34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41684-021-00755-6","article-title":"Nonhuman primate models for SARS-CoV-2 research: Consider alternatives to macaques","volume":"50","year":"2021","journal-title":"Lab Anim (NY)"},{"key":"2022081112050635000_2022.08.08.503239v1.35","doi-asserted-by":"crossref","first-page":"e1010162","DOI":"10.1371\/journal.ppat.1010162","article-title":"The pigtail macaque (Macaca nemestrina) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease","volume":"17","year":"2021","journal-title":"PLoS Pathog"},{"key":"2022081112050635000_2022.08.08.503239v1.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891"},{"key":"2022081112050635000_2022.08.08.503239v1.37","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.26.445838"},{"key":"2022081112050635000_2022.08.08.503239v1.38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMc2107799","article-title":"Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"2022081112050635000_2022.08.08.503239v1.39","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7034e4"},{"key":"2022081112050635000_2022.08.08.503239v1.40","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"2022081112050635000_2022.08.08.503239v1.41","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.4269\/ajtmh.21-0229","article-title":"Inactivation of SARS-CoV-2 Laboratory Specimens","volume":"104","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"2022081112050635000_2022.08.08.503239v1.42","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1080\/22221751.2020.1858177","article-title":"Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection","volume":"9","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2022081112050635000_2022.08.08.503239v1.43"},{"key":"2022081112050635000_2022.08.08.503239v1.44","doi-asserted-by":"crossref","unstructured":"C. S. Clancy et al., Histologic pulmonary lesions of SARS-CoV-2 in 4 nonhuman primate species: An institutional comparative review. Vet Pathol, 3009858211067468 (2021).","DOI":"10.1177\/03009858211067468"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2022.08.08.503239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:27:58Z","timestamp":1768447678000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.08.08.503239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":44,"URL":"https:\/\/doi.org\/10.1101\/2022.08.08.503239","relation":{},"subject":[],"published":{"date-parts":[[2022,8,9]]},"subtype":"preprint"}}